Biocon Limited
20th KM Hosur Road
Electronics City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423
CIN : L24234KA1978PLC003417

www.biocon.com

Date: July 15, 2016

The Manager
Dept. of Corporate Services – Listing
The Bombay Stock Exchange Limited
P J Tower, Dalal Street
Mumbai – 400 001

The Manager- Listing Department
National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra – East,
Mumbai - 400051

Dear Sir,

Sub: Press Release

Please find enclosed a copy of press release made by the Company, on the topic:

"Biocon's Insulin Glargine Launched in Japan"

Request you to kindly take the above intimation on record.

Thanking you.

Yours faithfully,

For Biocon Limited,

BIOCON LIMITED ☆ BANGALORE ☆

Authorised Signatory

Press Release

Biocon's Insulin Glargine Launched in Japan

Bangalore, India, July 15, 2016

Biocon Ltd. (BSE code: 532523, NSE: BIOCON), Asia's premier biopharmaceutical company, announced today that close on the heels of receiving approval for its Insulin Glargine from the Japanese regulator last quarter, its partner FUJIFILM Pharma Co., Ltd. (FFP) has launched the product in Japan today.

Insulin Glargine BS Injection Kit (FFP) has been developed & manufactured by Biocon, and is being commercialized by FFP in Japan. The product is a ready-to-use, prefilled disposable pen with 3 ml of 100IU Insulin Glargine. It will provide a high quality, yet affordable, world-class long-acting biosimilar basal Insulin Glargine for patients of diabetes in Japan. There were 7.2 million people with diabetes in Japan in 2015, according to the International Diabetes Federation.

The Company through its partner aims to capture a significant share of the Japanese Glargine market of US$ 144 Mn^, which is the second largest market outside of North America & Europe and is largely dominated by disposable pens.

Biocon Chairperson & Managing Director, Kiran Mazumdar-Shaw said: *"The launch of our biosimilar Insulin Glargine in Japan by our partner, furthers our mission to provide affordable access to high quality biopharmaceuticals for chronic diseases. We believe with FUJIFILM Pharma's commercial network, we will enable access to this world-class, prefilled disposable pen for better diabetes management for patients in Japan."*

Biocon is recognized as Asia's largest insulins producer and has been committed to affordable diabetes management through rh-Insulin (Insugen®) and Insulin Glargine (Basalog®) in India and several emerging markets. The company currently has marketing approvals in over 60 countries for rh-Insulin and in over 20 countries for Insulin Glargine. It is also developing Insulin Glargine for the developed markets outside of Japan in collaboration with Mylan.

^Source: IMS March 2015

About Biocon Ltd:

Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is India's largest and fully-integrated, innovation-led biopharmaceutical company. As an emerging global

biopharmaceutical enterprise serving customers in over 100 countries, it is committed to reduce therapy costs of chronic diseases like autoimmune, diabetes, and cancer. Through innovative products and research services it is enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. It has successfully developed and taken a range of biologics, novels as well as biosimilars, differentiated small molecules and affordable rh- insulin and analogs from 'Lab to Market'. Some of its key brands are INSUGEN®(rh-insulin), BASALOG® (Glargine), CANMAb™ (Trastuzumab), BIOMAb-EGFR™ (Nimotuzumab) and ALZUMAb ™(Itolizumab), a 'first in class' anti-CD6 monoclonal antibody. It has a rich pipeline of biosimilars and novel biologics at various stages of development including high potential oral insulin. Visit: www.biocon.com

Disclaimer:
Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither our company, our directors, nor any of our affiliates, have any obligation to update or otherwise revise any statements reflecting circumstances arising after this date or to reflect the occurrence of underlying events, even if the underlying assumptions do not come to fruition.

For More Information:	
Media Relations: **Seema Ahuja** VP & Global Head, Corporate Communications 080 2808 2222; +91 99723 17792 seema.ahuja@biocon.com	*Investor Relations:* **Saurabh Paliwal** Head, Investor Relations *+91 80 6775 2040; +91 95383 80801* *saurabh.paliwal@biocon.com*